Andrew E. Place, MD, PhD appointed as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center Vice President, Pediatric Chief Medical Officer
2024-03-28
(Press-News.org)
BOSTON -- Andrew E. Place, MD, PhD, has been named as Vice President, Pediatric Chief Medical Officer (CMO) at Dana-Farber Cancer Institute (within the Department of Pediatric Oncology) and Boston Children’s Hospital (within the Division of Hematology/Oncology) for the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.
In this role, Place will work closely with institutional and departmental leaders at Boston Children’s Hospital (BCH) and Dana-Farber to help define and implement clinical strategies and operational approaches that enhance smooth and efficient running of clinical care services across the institutions. He will have a major role in oversight of all clinical operations involving oncology and hematopoietic stem cell transplant patients at both institutions.
“I am thrilled and honored to lead the clinical operations of our Oncology and Bone Marrow Transplant programs. I look forward to working closely with our clinicians to deliver innovative, compassionate, and patient-centered care to children and young adults with cancer and blood disorders,” said Place.
Place received his PhD in Pharmacology and Toxicology from Dartmouth College in 2004 and his MD from the Geisel School of Medicine at Dartmouth in 2006. He completed his pediatric residency training in the Boston Combined Residency Program at BCH and Boston Medical Center. He subsequently completed a fellowship in pediatric hematology-oncology at BCH and Dana-Farber. In 2012, he became an attending physician in Pediatric Oncology at the Dana-Farber/Children’s Hospital Cancer Center, where he currently participates in the development of early phase clinical trials for children and adolescents with high risk leukemias.
Place has been a successful leader of Dana-Farber’s Pediatric Hematological Malignancies Program for the past 6 years during which time he also has served as the CMO of Boston Children’s Institutional Centers for Clinical and Translational Research. In these roles, Place gained significant institutional expertise in clinical and clinical research operations at both BCH and Dana-Farber.
“I believe that the growth and innovation of our clinical services will depend highly on strengthening the connectedness between our two world-class institutions. I anticipate developing and implementing a shared vision for our clinical services that focuses on delivering expert care and improving the experience of providing that care,” said Place.
Place is replacing Lisa Diller, MD who stepped down from the role at the end of 2023, after holding the CMO position since 2007. She continues to be a member of the leadership team in her role as Vice-Chair in the Department of Pediatric Oncology, focusing on Faculty Affairs, and as a leader at Dana-Farber representing clinical pediatric oncology in institutional initiatives and strategy.
About Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center combines expertise of Dana-Farber Cancer Institute and Boston Children’s Hospital to offer seamless, integrated care for children with all types of cancer and blood disorders — including the rarest and most complex cases. The Center performs more than 100 stem cell transplants each year and has performed over 1,500 stem cell transplants to-date, making it one of the largest and most experienced pediatric stem cell transplant programs in the world. Dana-Farber/Boston Children's was the first hospital in New England to offer MIBG therapy to treat high-risk neuroblastoma (including relapsed or refractory neuroblastoma) and is currently one of only about 10 hospitals in the country to provide this therapy. All patients have access to leading-edge precision medicine research which provides valuable information about their unique tumor profile. Additionally, Dana-Farber/Boston Children’s offers the most advanced treatments including CAR T-cell therapy, gene therapy and immunotherapy for children with cancer or blood disorders.
END
ELSE PRESS RELEASES FROM THIS DATE:
2024-03-28
UVA Health researchers have discovered a potential explanation for some of the most perplexing mysteries of COVID-19 and long COVID. The surprising findings could lead to new treatments for the difficult acute effects of COVID-19, long COVID and possibly other viruses.
Researchers led by UVA’s Steven L. Zeichner, MD, PhD, found that COVID-19 may prompt some people’s bodies to make antibodies that act like enzymes that the body naturally uses to regulate important functions – blood pressure, for example. Related enzymes also regulate ...
2024-03-28
Just as many people battle seasonal colds and flu, native plants face their own viral threats. People have long known that plants can succumb to viruses just like humans. Now, a new study led by Michigan State University and the University of California, Riverside reveals a previously unknown threat: non-native crop viruses are infecting and jeopardizing the health of wild desert plants.
“For years, the ecological field assumed wild plants were immune to invasive viruses that damage crops,” said Carolyn ...
2024-03-28
Fukuoka, Japan—Researchers from Kyushu University have developed a hydrogen energy carrier to address some of the biggest hurdles in the path towards a sustainable hydrogen economy. As explained in a paper published in JACS Au, this novel compound can efficiently “store electrons” from hydrogen in a solid state to use in chemical reactions later.
Hydrogen is a promising source of clean energy with a lot of untapped potential applications in industry and everyday life. Unlike conventional fuels, hydrogen can be used to generate electricity without producing greenhouse ...
2024-03-28
Scientists at The Florey have developed an mRNA technology approach to target the toxic protein tau, which builds up in patients with Alzheimer’s disease and other dementias.
To date, mRNA has been predominantly used for vaccines, including those used to fight COVID-19.
New research published today in Brain Communications establishes The Florey as a key player in the mRNA field, with Dr Rebecca Nisbet taking the technology in a new direction.
“This is the first time mRNA has been explored for use in Alzheimer’s disease,” Dr Nisbet said. “Our work in cell models demonstrates that this technology ...
2024-03-28
East Hanover, NJ – March 28, 2024 – Kessler Foundation received two grants from The New Jersey Commission on Spinal Cord Research that will fuel innovative research in the field of spinal cord injury (SCI). These grants will fund efforts aimed at improving the cognitive assessment of individuals with traumatic SCI and pilot-testing the first-of-its-kind Spinal Cord Injury Personal Assistance Services Survey (SCI-PASS).
Traumatic spinal cord injury (tSCI) often leads to cognitive impairment, affecting up to 60 percent of individuals living with this condition. “The challenge lies in assessing cognitive functions in people with tSCI, as many existing tests rely on upper limb ...
2024-03-28
Rising temperatures and disease outbreaks are decimating coral reefs throughout the tropics. Evidence suggests that higher latitude marine environments may provide crucial refuges for many at-risk, temperature-sensitive coral species. However, how coral populations expand into new areas and sustain themselves over time is constrained by the limited scope of modern observations.
What can thousands of years of history tell us about what lies ahead for coral reef communities? A lot. In a new study, Florida Atlantic University researchers and collaborators provide geological insights into coral range expansions by reconstructing the composition of a Late Holocene-aged subfossil coral ...
2024-03-28
Fukuoka, Japan—The interaction between the oceans and the atmosphere plays a vital role in shaping the Earth’s climate. Changing sea surface temperatures can heat or cool the atmosphere, and changes in the atmosphere can do the same to the ocean surface. This exchange in energy is known as “ocean-atmosphere coupling.”
Now, researchers from Kyushu University have revealed that this ocean-atmosphere coupling enhances teleconnection patterns—when climate conditions change across vast regions of the globe—in the Northern Hemisphere. In their recent ...
2024-03-28
Low recurrence seen with cryoablation for large breast tumors
Cryoablation, a minimally invasive technique used to freeze and destroy small tumors, is effective for breast cancer patients with larger tumors, according to research presented by MSK interventional radiologist Yolanda Bryce, MD, at the 2024 Society of Interventional Radiology Annual Scientific Meeting.
The retrospective study assessed outcomes for 60 patients who underwent cryoablation because they were not candidates for surgery or declined surgery due to other health concerns. The average size of their tumors was 2.5 centimeters. In a follow-up after 16 months, only 10% of patients experienced a recurrence ...
2024-03-28
MANDAN, N.D., March 28, 2024—The U.S. Department of Agriculture (USDA) Agricultural Research Service (ARS) announces a cooperative agreement with the Nueta Hidatsa Sahnish (NHS) College to conduct research supporting Indigenous Seed Sovereignty. This collaborative effort will increase the number of traditional varieties of seeds of the Mandan, Hidatsa, and Arikara (MHA) Nation crops within NHS College's traditional seed cache.
This agreement builds upon USDA’s strengthened partnerships with ...
2024-03-28
Younger women are generally thought to have a low risk of heart disease, but new research urges clinicians to revisit that assumption, especially for women who suffer from certain mental health conditions. A new study being presented at the American College of Cardiology’s Annual Scientific Session found that having anxiety or depression could accelerate the development of cardiovascular risk factors among young and middle-aged women.
The study draws new attention to the importance of cardiovascular screening and preventive care as rates of cardiovascular risk factors rise and heart attacks become more common in younger people. Anxiety and depression ...
LAST 30 PRESS RELEASES:
[Press-News.org] Andrew E. Place, MD, PhD appointed as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center Vice President, Pediatric Chief Medical Officer
